Navigation Links
Cell-death receptor links cancer susceptibility and inflammation
Date:12/27/2007

PHILADELPHIA - For over 10 years, Wafik S. El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology at the University of Pennsylvania School of Medicine, has been pursuing a cancer-targeting molecule called TRAIL and its molecular partners. TRAIL is normally produced by immune cells and curtails tumor spread by binding to a specialized receptor on a tumors surface.

However, in cancer patients who often have suppressed immunity, and for reasons we still dont understand, there isnt enough TRAIL being produced, so tumors are not suppressed, explains El-Deiry, who is also Co-Program Leader of the Radiation Biology Program for the Abramson Cancer Center at Penn.

Most recently, El-Deiry and colleagues demonstrated for the first time a link between TRAILs receptor and cancer susceptibility, as reported online December 13, 2007 in the Journal of Clinical Investigation in advance of the January 2008 print issue. Unexpectedly, they also found a connection via Trail between inflammation and cancer susceptibility.

Mice engineered without the TRAIL receptor on their cells versus healthy controls developed larger and more tumors in their livers and other organs after being challenged with a chemical carcinogen or radiation. The team also bred TRAIL receptor knock-out mice with mice genetically engineered to get B-cell lymphomas that metastasize to the liver. Their offspring displayed more liver tumors compared to controls. This is the first direct in vivo evidence that loss of the tumor death-inducing TRAIL receptor confers cancer susceptibility, says El-Deiry.

When intact, TRAIL and its receptor decrease the influx of inflammatory cells and molecules that can lead to cancer. New models of cancer have suggested a link between inflammation and cancer in the last five years, and El-Deiry is in the early stages of trying to understand this connection with respect to the TRAIL pathway.

For example, in this study, the
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
3. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
4. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
5. Food restriction increases dopamine receptor levels in obese rats
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
8. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
9. Receptor protein appears to be key in breakdown of kidney filtration
10. Pathway links inflammation, angiogenesis and breast cancer
11. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , UNION, N.J., Dec. 4 P...ded its specialty anatomic pathology services with...ring. The new service completes the company,s expa...onal anatomic pathology company offering diagnosti...uding gastroenterology, urology and now hematology...
(Date:12/4/2009)...For obese men, a dramatic weight loss can be an ef...noea, scientists at the Swedish medical university...leep apnoea when the study began benefited most fr...ight loss may be an effective treatment strategy f..., one of the researchers involved in the study. ,...
(Date:12/4/2009)... Bobby Berk Home & Auth...nounce their 1st annual Toy Drive benefiting Provi...hristmas” program. The goal is to raise $500... that goal is achieved, Bobby Berk Home will match...s Saturday, December 19th at Providence Hospital. ...
(Date:12/4/2009)..., , LOS ANGELES, Dec. 4 Yog...merate, announced today the launch of its holiday ...Chip . On December 7, the new festive mixes will b...ca. Yogen Fruz,s low-calorie Yog-Nog and Mint Choc...ee dessert alternative to indulge in this holiday ...
(Date:12/4/2009)... North American Seminars In...o host continuing medical education courses at the... facility to showcase its operation and capabiliti...r overall costs to educate their physical therapy ...r 45 facilities hosted over 250 live training even...
Breaking Medicine News(10 mins):Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:Weight-loss proves effective cure for sleep apnea 2Health News:Weight-loss proves effective cure for sleep apnea 3Health News:Bobby Berk Home and Leslie Sanchez Announce 1st Annual Toy Drive for DC's Neediest Families 2Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4
...llergy is a common affliction across the world esp...phere. //In the USA it affects more than 50 millio...congestion and post nasal drip lead to more seriou...and Neck Surgeon at , of Methodist Dallas Medical ...
...esearchers say about 1 million people in the Unite... the body destroys insulin-producing beta // cells...ay help people with type 1 diabetes reduce their r...ntense diabetes control. Patients in the stand...
...he latest research uncovers more evidence that soy...a rich source of isoflavones and also may contain ...nd to be beneficial for breast cancer and prostate...the uterus. Researchers interviewed 832 women w...
...ach year in the United States, about 35,000 people...0 will die. Now, a new test gets closer to an earl...itta found a lump that turned out to be kidney can...wed uncertain results. "Seventy percent to 90...
...laucoma is currently the world’s second leading ca...nd the world are affected by glaucoma.//New resear...ure pressure in the eye when screening people for ...esearchers say instead of doctors just looking at ...
...ach year in the United States, 1 million cases of ...ple are living with // actinic keratoses and more ...ng a new therapy to keep the cancer from developin...tdoor person.” All that sun damaged her legs -- ca...
Other Medicine News:Health News:Urine Test for Kidney Cancer 2
(Date:12/3/2009)...- Guidepoint Global, LLC , a leading primary rese...ep Apnea Tracker, a monthly longitudinal data rele...hare in the worldwide Sleep Apnea market. ,, T...ge for 87 different Sleep Apnea mask brands sold i...oviders going back to January 2006. In the most r...
(Date:12/3/2009)...e-FirstCall/ -- A genetic variation that may indic...ife-threatening blood disorder if exposed to certa... several medical discoveries scientists at cancer ...) will present during the 51st American Society of...ecember 5-8, 2009, in New Orleans, LA. ,, In 1...
(Date:12/3/2009)...rstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR...lease with Regeneron Pharmaceuticals, Inc. (Nasdaq... additional, newly-constructed laboratory and offi...rytown, New York. The new lease expires on June 30...ed approximately two months after BioMed and Regen...
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 1HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 2HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 13683 1Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 13683 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 13683 3Unlocking the bodys defenses against cancer 55267 1Unlocking the bodys defenses against cancer 55267 2
...cals, a division of Wyeth (NYSE: WYE ), presented...ifene, a selective estrogen receptor,modulator, at...h Annual,Meeting. In a three-year study, data show... reduced the relative risk of new vertebral fractu...mpared with placebo. A post-hoc,subgroup analysis ...
...tion today,announced that it has dosed its first p...1001, an inhibitor of gastrointestinal barrier dys...nts with Celiac Disease (CD). The,multi-center, do... will,evaluate the efficacy, safety and tolerabili...ten challenge, while also testing components of a,...
Other Medicine Technology:Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 2Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 3Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 4Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease 2
Optiray®
... contrast medium for intravascular and body cavity... of clinical experience and use in over 3.5 millio...able part of the team effort in hundreds of radiol...itoring trials1-3 confirm that IMAGOPAQUE is a wel...
...ontrast medium for Magnetic Resonance Imaging (MRI...r intravenous injection. In MRI, ProHance® pr...d surrounding tissues resulting in improved visual...with abnormal vascularity or those thought to caus...
...ides) is Advanced Magnetics' contrast agent for us...is the first organ-specific MRI contrast agent to ... function, the agent is taken up by macrophages fo...mors. The liver is a principal site for metastasis...
Medicine Products: